Trial search - ClinicalTrials.eu

Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

↓

Matched clinical trials

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Recruiting

1 1 1
Investigated diseases:
- Pleural mesothelioma
Investigated drugs:
- Cemiplimab
- Fianlimab
Study on the Use of 68Ga-FAPI-46 and Fludeoxyglucose (18F) for Diagnosing Pleural Mesothelioma in Patients

Recruiting

1 1 1
Investigated diseases:
- Pleural mesothelioma
Investigated drugs:
- (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
- Fludeoxyglucose (18F)
Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

Not yet recruiting

1 1 1 1
Investigated diseases:
Investigated drugs:
Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations

Not yet recruiting

1 1 1
Investigated diseases:
- Pleural mesothelioma
- Non-small cell lung cancer
Investigated drugs:
- Dostarlimab
- Niraparib
Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Not recruiting

1 1 1 1
Investigated diseases:
- Pleural mesothelioma
Investigated drugs:
+3

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes